WellBeing International

WBI Studies Repository
3-2019

CRISPR-Mediated Gene Editing: Scientific and Ethical Issues
Jarrod Bailey
Cruelty Free International

Follow this and additional works at: https://www.wellbeingintlstudiesrepository.org/geneti
Part of the Animal Studies Commons, Other Animal Sciences Commons, and the Other Genetics and
Genomics Commons

Recommended Citation
Bailey, J. (2019). CRISPR-Mediated Gene Editing: Scientific and Ethical Issues. Trends in biotechnology.
https://doi.org/10.1016/j.tibtech.2019.05.002

This material is brought to you for free and open access
by WellBeing International. It has been accepted for
inclusion by an authorized administrator of the WBI
Studies Repository. For more information, please contact
wbisr-info@wellbeingintl.org.

TIBTEC 1795 No. of Pages 2

Trends in Biotechnology

Letter

CRISPR-Mediated Gene
Editing: Scientiﬁc and
Ethical Issues
Jarrod Bailey

1,

*

There remains substantial evidence to warrant great concern
over the poor efﬁciency and
speciﬁcity of clustered regularly
interspaced short palindromic repeats (CRISPR)-mediated genetic
modiﬁcation (GM), despite relatively minor improvements compared to other GM methods.
These issues cause persistent,
adverse, ethical, and scientiﬁc
consequences for GM animals,
which may never be sufﬁciently
resolvable.
An article recently published in Trends in
Biotechnology discussed how engineering
of guide RNAs could improve the efﬁciency and speciﬁcity of CRISPR [1].
While this technique may have great
potential for aiding research into the
understanding of gene function in the
future, and for eventual clinical applications, such as gene therapy, the authors
may have been over-optimistic and
speculative, and insufﬁciently critical.
While they acknowledge some caveats
(only a small set of target genes has
been investigated), and the need for
further improvements (in increasing
efﬁciency, speciﬁcity, and obviating
toxicity), it is important to provide
more balance, as there exists signiﬁcant
evidence warranting great caution on
several levels, which seems underappreciated. This is particularly relevant to
the creation of GM animals, which
will be an area in which CRISPR is
heavily used, and for which there are
serious ethical/welfare consequences
and considerations.

I recently questioned claims about
CRISPR’s high degree of efﬁciency and
speciﬁcity, and reviewed the evidence
supporting a much more prudent approach,
which is urged by some stakeholders [2]. To
illustrate, recent reports have highlighted
slightly improved, though still very poor
efﬁciencies, which when one looks for precision, amount to a few percent at most [3].
Off-target effects are persistent, even with
engineered CRISPR components, and can
have multiple pathogenic consequences,
including cancer. Many off-target effects
are missed due to analytical methods
that aren’t sufﬁciently comprehensive, and
– crucially – some believe they may never
be completely removed, however high ontarget speciﬁcity may become [4,5]. Ontarget effects may often be more signiﬁcant
than intended, causing large deletions and
genomic rearrangements. CRISPR is also
more likely to be successful in cells in
which the p53 gene is deﬁcient, and so
has further cancerous potential – with catastrophic consequences for GM animals
and for clinical applications [6,7]. This tumorigenicity does not arise solely from CRISPR,
so other contributory factors must be
identiﬁed. While cells could be selected to
avoid this, it is not possible for in vivo applications. Perhaps alarmingly, these issues
have not led to the cautious approach they
justify, and which some scientists urge.
This is partly evidenced by clinical trials of
the technology, which has been used for
various malignancies/cancers.
These concerns are in addition to other
long-standing problems associated with
the creation of, and experimentation on,
GM animals. While these issues could not
be expected to be addressed by the authors of the recent Trends in Biotechnology
paper, they are relevant to the use of
CRISPR in science, and substantiate the
call for a much more cautious attitude.
Poor efﬁciency and speciﬁcity are acknowledged to be a serious welfare issue, with
every stage of the creation and breeding of
GM animals potentially involving pain and
suffering to some degree, and which may

not be fully appreciated and taken into account in harm–beneﬁt analyses [8,9]. There
exists signiﬁcant evidence of failed translation of data from GM animals to human
beneﬁt, and of their poor human relevance
for many diseases [2]. Of salient concern
currently is the increased creation of, and
experimentation on, GM monkeys, partly in
response to greater appreciation of the
inadequacies of GM mice. It has been
suggested that they will be more human
relevant, but there is little or no evidence to
support this. They will be subject to the
same inefﬁciencies and lack of speciﬁcity
as GM mice, due to the aforementioned
(and possibly persistent) inadequacies of
CRISPR, and there are myriad confounding
differences in gene complement and expression between humans and monkeys,
which will always affect – and preclude –
their applicability to humans [10].
Finally, it is important to note that many who
oppose the application GM technology to
animals for ethical and scientiﬁc reasons,
do not oppose its use in basic science involving cell and tissue cultures, which will
become more informative and human relevant with further advances in 3D culture,
organoids, body-on-a-chip approaches,
stem cells, and so on. These techniques
are already being used to investigate gene
function, link genetic mutations/polymorphisms with phenotype, attempt gene therapy, etc. It is these human relevant in vitro
methods that will determine if CRISPR can
be sufﬁciently safe and reliable to be used
in human patients (along the lines that
Moon and colleagues [1] suggest). There is
no scientiﬁc necessity to develop CRISPR
in animals, or scientiﬁc basis to assume
that successful and 'safe' gene therapy in,
say, mice or monkeys, will translate to the
same in human patients.
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